CAMBRIDGE, Mass.--(BUSINESS WIRE)--Goldfinch Bio, a U.S.-based, clinical stage biotechnology company focused on discovering and developing precision medicines for the treatment of kidney diseases, ...

CAMBRIDGE, Mass., Dec. 5, 2017 /PRNewswire/ -- Goldfinch Bio, a company focused on precision therapies to treat patients with kidney disease, today announced the appointments of industry veterans ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Goldfinch Bio, a biotechnology company focused on discovering and developing precision medicines for the treatment of genetically-driven kidney diseases, today ...

After Ardelyx cut a majority of its workforce this autumn, it appears a 13-year veteran was one to say goodbye. Jeff Jacobs, Ph.D., is headed to Goldfinch Bio to lead scientific operations of the ...

When Tony Johnson departed AstraZeneca last year, he was just the latest in a string of Big Pharma executives to move into, or back into, biotech. With no hands-on experience running a biotech company ...

(RTTNews) - Gilead Sciences, Inc. (GILD) has announced a strategic collaboration Goldfinch Bio, Inc. which will leverage Goldfinch's Kidney Genome Atlas platform to identify new therapeutic targets ...

Gilead Sciences will partner with Goldfinch Bio to discover, develop, and commercialize new therapeutics for diabetic kidney disease (DKD) and orphan kidney diseases, the companies said today, through ...

Please provide your email address to receive an email when new articles are posted on . Biopharmaceutical company Karuna Therapeutics has announced an exclusive license agreement with biotech firm ...

Karuna to obtain exclusive global license to develop, manufacture, and commercialize multiple TRPC4/5 candidates, including lead clinical-stage candidate GFB-887 Goldfinch Bio assignment estate to ...

Goldfinch Bio, a Cambridge, Mass., biotech startup seeking to develop precision medicines for people with kidney disease, will receive at least $109 million in a business deal with the California ...

Gilead Sciences, Inc. GILD, which recently suffered setbacks in non-alcoholic steatohepatitis drug development and is left to contend with a maturing HIV franchise, is looking elsewhere to develop its ...

Goldfinch Bio, a Cambridge biotech startup seeking to develop precision medicines for people with kidney disease, will receive at least $109 million in a business deal with the California biopharma ...